196 related articles for article (PubMed ID: 38548807)
1. Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors.
Panwar P; Olesen JB; Blum G; Delaisse JM; Søe K; Brömme D
Sci Rep; 2024 Mar; 14(1):7358. PubMed ID: 38548807
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
[TBL] [Abstract][Full Text] [Related]
3. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
4. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.
Panwar P; Law S; Jamroz A; Azizi P; Zhang D; Ciufolini M; Brömme D
Br J Pharmacol; 2018 Mar; 175(6):902-923. PubMed ID: 29278432
[TBL] [Abstract][Full Text] [Related]
5. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
[TBL] [Abstract][Full Text] [Related]
6. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
8. An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.
Panwar P; Xue L; Søe K; Srivastava K; Law S; Delaisse JM; Brömme D
J Bone Miner Res; 2017 Dec; 32(12):2415-2430. PubMed ID: 28745432
[TBL] [Abstract][Full Text] [Related]
9. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
Panwar P; Søe K; Guido RV; Bueno RV; Delaisse JM; Brömme D
Br J Pharmacol; 2016 Jan; 173(2):396-410. PubMed ID: 26562357
[TBL] [Abstract][Full Text] [Related]
11. Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption.
Ren ZY; Machuca-Gayet I; Domenget C; Buchet R; Wu Y; Jurdic P; Mebarek S
PLoS One; 2015; 10(7):e0132513. PubMed ID: 26168340
[TBL] [Abstract][Full Text] [Related]
12. Pit- and trench-forming osteoclasts: a distinction that matters.
Merrild DM; Pirapaharan DC; Andreasen CM; Kjærsgaard-Andersen P; Møller AM; Ding M; Delaissé JM; Søe K
Bone Res; 2015; 3():15032. PubMed ID: 26664853
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits.
Pennypacker BL; Oballa RM; Levesque S; Kimmel DB; Duong LT
BMC Musculoskelet Disord; 2013 Dec; 14():344. PubMed ID: 24321244
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
15. Investigation of osteoclast cathepsin K activity in osteoclastogenesis and bone loss using a set of chemical reagents.
Janiszewski T; Kołt S; Ciastoń I; Vizovisek M; Poręba M; Turk B; Drąg M; Kozieł J; Kasperkiewicz P
Cell Chem Biol; 2023 Feb; 30(2):159-174.e8. PubMed ID: 36696904
[TBL] [Abstract][Full Text] [Related]
16. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
17. Altered hematopoietic stem cell and osteoclast precursor frequency in cathepsin K null mice.
Jacome-Galarza C; Soung do Y; Adapala NS; Pickarski M; Sanjay A; Duong LT; Lorenzo JA; Drissi H
J Cell Biochem; 2014 Aug; 115(8):1449-57. PubMed ID: 24590570
[TBL] [Abstract][Full Text] [Related]
18. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
19. A patent review on cathepsin K inhibitors to treat osteoporosis (2011 - 2021).
Rocho FR; Bonatto V; Lameiro RF; Lameira J; Leitão A; Montanari CA
Expert Opin Ther Pat; 2022 May; 32(5):561-573. PubMed ID: 35137661
[TBL] [Abstract][Full Text] [Related]
20. Identification of substrate-specific inhibitors of cathepsin K through high-throughput screening.
Law S; Du X; Panwar P; Honson NS; Pfeifer T; Roberge M; Brömme D
Biochem J; 2019 Feb; 476(3):499-512. PubMed ID: 30622151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
